Duloxetine and the SNRIs Deep Dive Part 2
Psychiatry & Psychotherapy Podcast
David J Puder
4.8 • 1.4K Ratings
🗓️ 17 April 2021
⏱️ 51 minutes
🧾️ Download transcript
Summary
In today's episode of the podcast, we'll be continuing our deep dive into duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI). In this second part, we'll be covering the approved indications and off-label uses of duloxetine.
By listening to this episode, you can earn 0.75 Psychiatry CME Credits.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Hello and welcome to the Psychiatry and Psychothermic Podcast. |
| 0:12.2 | I'm here to talk about getting rid of burnout, increasing job satisfaction, and feeling |
| 0:16.6 | like an expert in what you do. |
| 0:18.6 | One thing that created a lot of burnout and angst for me was trying to get continued medical |
| 0:22.0 | education right at the last minute. |
| 0:24.2 | So why not join the CME membership and do CME while listening to this podcast? |
| 0:28.6 | Go to Psychiatrypodcast.com, sign up, sign in, take the test, and the certification |
| 0:32.5 | is email to you in seconds. |
| 0:35.5 | Welcome back to the podcast. |
| 0:36.6 | I am here with Dr. Cummings. |
| 0:38.9 | We are going to be doing part two of deloxetine and SNRIs. |
| 0:43.6 | And today our focus is going to be on the efficacy of the medications. |
| 0:49.0 | And yeah, welcome to the podcast Dr. Cummings. |
| 0:51.3 | Thank you. |
| 0:52.3 | I'm happy to be back and do part two. |
| 0:55.2 | Indeed, we're talking about deloxetine as well as some of the other SNRIs, just to bring |
| 1:02.4 | people back to the primary drug. |
| 1:05.5 | We're talking about deloxetine as a serotonin or epinephrine reuptake inhibitor, meaning |
| 1:11.5 | it blocks the transport for serotonin and for norepinephrine. |
| 1:17.0 | It was introduced into the market by Eli Lilly and company in 2004, initially indicated |
| 1:23.8 | by the FDA for treatment of major depressive disorder, then neuropathic pain related |
| 1:29.3 | to diabetes, albeit that indication has grown into other areas, generalized anxiety disorder |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from David J Puder, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of David J Puder and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.